Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
Ashish M. Kamat, Thomas W. Flaig, H. Barton Grossman et al. · Nature Reviews Urology · 2015
A focus group of specialized urologic oncologists has reviewed guidelines and clinical evidence and discussed their experiences regarding the optimal use of BCG in the management of patients with NIMBC. Here, they provide a review of BCG therapy, clarify complex related topics and recommend best practice guidelines to improve BCG use and patient outcomes. Multiple clinical trials have demonstrated that intravesical Bacillus Calmette–Guérin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC). However, although BCG has been in use for almost 40 years, this agent is often underutilized and practice patterns of administration vary. This neglect is most likely caused by uncertainties about the optimal use of BCG, including unawareness of optimal treatment schedules and about patient populations that most benefit from BCG treatment. To address this deficit, a focus group of specialized urologic oncologists (urologists, medical oncologists and radiation oncologists) reviewed the current guidelines and clinical evidence, discussed their experiences and formed a consensus regarding the optimal use of BCG in the management of patients with NIMBC. The experts concluded that continuing therapy with 3-week BCG maintenance is superior to induction treatment only and is the single most important factor in improving outcomes in patients with NMIBC. They also concluded that a reliable alternative to radical cystectomy in truly BCG-refractory disease remains the subject of clinical trials. In addition, definitions for common terms of BCG failure, such as BCG-refractory and BCG-intolerant, have been formulated.
Cited by 252 works. doi:10.1038/nrurol.2015.58 Open-access PDF
Authors
- Ashish M. Kamat
- Thomas W. Flaig
- H. Barton Grossman
- Badrinath R. Konety
- Donald L. Lamm
- Michael A. O’Donnell
- Edward Uchio
- Jason Alexander Efstathiou
- John Arthur Taylor
References
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
- The National Comprehensive Cancer Network
- ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction
- Effects of Intensive Glucose Lowering in Type 2 Diabetes